Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients aged ≥ 6 years and ≤ 65 years on the day informed consent is obtained~2. Patients diagnosed with TSC based on the clinical diagnostic criteria of International Tuberous Sclerosis Complex Consensus Conference 2012 and presenting visible facial angiofibroma~3. An FA severity score of 2 or 3 on the IGA scale~4. Patients or their legal representatives capable of understanding the explanation of the clinical trial and who give written informed consent for participation~5. Patients or their legal representatives able to maintain patient diaries following the instructions of the investigator or sub-investigator~Exclusion Criteria:~1. Patients who cannot carry out the treatment plan or follow-up assessment~2. Patients with serious skin lesions such as erosions or ulcers~3. Patients with known hypersensitivity to any component of the study product~4. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment~5. Patients who received laser therapy or surgical therapy within 6 months prior to trial enrolment~6. Patients who participated in any other clinical trial within 3 months prior to the day of enrolment~7. Patients judged unsuitable for this clinical trial by the investigator or sub-investigator~8. Pregnant or lactating females~9. Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception~10. Patients with immune dysfunction or receiving any form of immunosuppression~11. Patients with severe FA, with a score of 4 on the IGA scale~12. Patients with an FA severity score of less than 2 on the IGA scale

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.5% Rapamycin cream, topical (Type: EXPERIMENTAL): Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
- 1.0% Rapamycin cream, topical (Type: EXPERIMENTAL): Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo cream topical, applied once daily before bed on affected area for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).